{"filing":{"accession_number":"0001104659-26-068604","cik":"0001661059","ticker":"NXTC","company_name":"NextCure, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"nxtc-20260601x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926068604/nxtc-20260601x8k.htm"},"events":[{"id":7705,"run_id":6769,"accession_number":"0001104659-26-068604","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"NextCure disclosed Phase 1 dose escalation data for SIM0505 presented at ASCO 2026, showing a 55% objective response rate in gynecologic cancer patients with a manageable safety profile, along with updated corporate presentation materials reflecting pipeline updates. For a clinical-stage biopharmaceutical company, disclosure of Phase 1 clinical trial data at a major medical conference is material to investors assessing pipeline progress and development trajectory.","company_name":"NextCure, Inc.","ticker":"NXTC","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3009,"accession_number":"0001104659-26-068604","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"NextCure disclosed Phase 1 dose escalation data for its investigational drug candidate SIM0505 presented at ASCO 2026, along with updated corporate presentation materials reflecting pipeline updates and interim phase 1 data. For a clinical-stage biopharmaceutical company, disclosure of Phase 1 clinical trial data at a major medical conference is material to investors assessing the company's pipeline progress and development trajectory. However, this does not fit neatly into the standard event taxonomy (not an earnings release, M\u0026A activity, impairment, or other defined categories), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:15:01.384748+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3010,"accession_number":"0001104659-26-068604","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure combines two distinct material events: (1) Phase 1 clinical trial data for SIM0505 showing a 55% ORR in gynecologic cancer patients and manageable safety profile, which is significant for a clinical-stage biotech company's pipeline advancement; and (2) a going-concern-adjacent liquidity statement indicating cash sufficiency only through Q1 2027 with explicit acknowledgment of risk of earlier depletion. While the clinical data is positive and material to investors assessing pipeline value, the liquidity disclosure—though not a formal going-concern opinion—signals near-term capital constraints. The Item 8.01 classification and mixed nature of clinical progress plus liquidity risk best fit \"other_material\" rather than a single specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:15:01.384748+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3009,"accession_number":"0001104659-26-068604","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"NextCure disclosed Phase 1 dose escalation data for its investigational drug candidate SIM0505 presented at ASCO 2026, along with updated corporate presentation materials reflecting pipeline updates and interim phase 1 data. For a clinical-stage biopharmaceutical company, disclosure of Phase 1 clinical trial data at a major medical conference is material to investors assessing the company's pipeline progress and development trajectory. However, this does not fit neatly into the standard event taxonomy (not an earnings release, M\u0026A activity, impairment, or other defined categories), warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:15:01.384748+00:00","company_name":"NextCure, Inc.","ticker":"NXTC","filing_date":"2026-06-01"},{"id":3010,"accession_number":"0001104659-26-068604","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure combines two distinct material events: (1) Phase 1 clinical trial data for SIM0505 showing a 55% ORR in gynecologic cancer patients and manageable safety profile, which is significant for a clinical-stage biotech company's pipeline advancement; and (2) a going-concern-adjacent liquidity statement indicating cash sufficiency only through Q1 2027 with explicit acknowledgment of risk of earlier depletion. While the clinical data is positive and material to investors assessing pipeline value, the liquidity disclosure—though not a formal going-concern opinion—signals near-term capital constraints. The Item 8.01 classification and mixed nature of clinical progress plus liquidity risk best fit \"other_material\" rather than a single specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:15:01.384748+00:00","company_name":"NextCure, Inc.","ticker":"NXTC","filing_date":"2026-06-01"}]}